Reasons for our high estimates of nonadherence in patients with prediabetes could be that gastrointestinal adverse effects have been reported in association with GLP‐1 RA treatment, and it is reasonable to speculate that patients with prediabetes might exhibit a reduced willingness to tolerate these effects.35, 36. This evidence concerns the gene GLP1R and prediabetes syndrome.